Pharmaco therapeutics

Identification of the medicinal product (name, form, strength, pharmaco-therapeutic group)... 

The study of China s alchemical tradition can provide considerable insight into early Chinese medical theory, pharmaco-therapeutic practice and psychosomatic concepts. Chinese alchemy is a complex blending of philosophical, cosmological, physiological and natural scientific thought. This article presents a historical survey and analysis of some important aspects of Chinese alchemical research and theory"... 

Epilepsy is a chronic brain disease of diverse etiology it is characterized by recurrent paroxysmal episodes of uncontrolled excitation of brain neurons. Involving larger or smaller parts of the brain, the electrical discharge is evident in the electroencephalogram (EEG) as synchronized rhythmic activity and manifests itself in motor, sensory, psychic, and vegetative (visceral) phenomena Because both the affected brain region and the cause of abnormal excitability may differ, epileptic seizures can take many forms. Erom a pharmaco-therapeutic viewpoint, these may be classified as ... 

Z0255 Sircar, N.N. PharmacO therapeutics of Z0267 Dasemani drugs. Ancient Sci Life 1984 3(3) 132-135. 

Surgical removal of the inflamed synovial membrane (synovectomy) frequently provides long-term relief. If feasible, this approach is preferred because all pharmaco-therapeutic measures entail significant adverse effects. 

Within 2 months the Pharmaco-therapeutic Secretariat of the NDI shall send the proposals of the Specialized Commissions (attached to the MA) to the MOH. Within 1 month of receiving the proposals, the MOH shall sign the MA (See Figure 2). 

Name of product, statement of active ingredients, pharmaceutical form, pharmaco-therapeutic group, name and address of authorisation holder. 

In order to meet the pharmaco-therapeutic needs of PFPB users, the Ministry of Health established a list of medicines based on the National Essential Medicines List, which was defined using epidemiological criteria, taking into account the principal diseases that affect the Brazilian population and the treatments that have the greatest impact... 

T. I. WiUiams, Drugs from P/ants Sigma, London, 1947, p. 87 L. S. Goodman and A. Gilman, The Pharmaco/ogica/Basis of Therapeutics A. Textbook of... 

The investigation of tolerability must cover a number of doses thought to be in the range required for therapeutic benefit. The relevance of these data can only be interpreted when they are related to plasma concentrations and, when appropriate, measurements of pharmaco-d)mamic activity. Adverse reactions occurring at 10 times the therapeutic dose may not pose a problem conversely, the absence of adverse reactions at one-tenth the therapeutic dose is of little relevance and, if misinterpreted, may give unfounded confidence. This may seem obvious but has important implications for study design that are frequently ignored (see Section 4.7). 

In turn, whether significant pharmacokinetic differences arising from the pol)nnorphisms translate into relevant alterations in pharmaco-d)mamics (and clinical efficacy) depends on the operating region of the concentration-response relationship, therapeutic index and utility, and whether kinetic variability is outweighed by variability in receptor sensitivity or number, or in the turnover of the natural receptor ligand. 

Benzodiazepine anxiolytics and hypnotics lead to a decrease in alpha and an increase in beta activity in pharmaco-EEG trials. With regard to theta and delta activities, the results of different studies vary. Buspirone at the usual therapeutic doses induces no or only a very weak EEG effect (Greenblatt et al., 1994) and is thus differentiated from the benzodiazepine anxiolytics. 

One strategy being used for a full assessment of the pharmaco/toxicokinet-ics of oligonucleotide therapeutics is to perform a mass balance study with... 

Platinum coordination complexes have been investigated as potential anticancer agents since 1972. The most successful of these is the cis dichlor-diammine platinum(II) complex which is particularly effective for the treatment of ovarian and testicular carcinomas. However, effective therapy requires high doses, typically 4.0/umol (825/ig)kg-1 given intravenously, which produce unpleasant and toxic reactions. Pharmaco-kinetic studies of the various Pt species in plasma indicate that the active species is of low molecular weight and the protein bound Pt species is apparently inactive [106]. Further work is needed to identify the active species and to develop therapeutic procedures that produce maximum anti-tumour activity with minimum toxicity. 

---